Anzeige
❌
Mehr »
Montag, 05.10.2026 - Börsentäglich über 12.000 News
Die Jobs, die keine KI der Welt ersetzen kann - und das Unternehmen dahinter
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1J7EB | ISIN: FR0011341205 | Ticker-Symbol: 5NR
Stuttgart
02.10.26 | 21:56
22,800 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
CAC Mid 60
1-Jahres-Chart
NANOBIOTIX SA Chart 1 Jahr
5-Tage-Chart
NANOBIOTIX SA 5-Tage-Chart
RealtimeGeldBriefZeit
22,56023,32007:20
22,70023,12007:20

Aktuelle News zur NANOBIOTIX Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
NANOBIOTIX Aktie jetzt für 0€ handeln
DoNanobiotix names new CFO4
DoNanobiotix S.A. - 6-K, Report of foreign issuer4
DoNanobiotix S.A.: NANOBIOTIX Announces the Appointment of Arnd Christ as Chief Financial Officer170PARIS and CAMBRIDGE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the "Company"), a late-stage clinical biotechnology company pioneering physics-based approaches...
► Artikel lesen
28.09.Can J&J's Partnership Drive More Upside for Nanobiotix?11
24.09.Nanobiotix GAAP EPS of -€0.70, revenue of €5.6M3
24.09.Nanobiotix S.A.: NANOBIOTIX Provides First Half 2026 Operational and Financial Update228Promising early results reported from full cohort analysis of the completed dose-escalation and expansion phases of a Phase 1 study evaluating JNJ-1900 (NBTXR3) for patients with inoperable, locoregionally...
► Artikel lesen
22.09.Nanobiotix S.A.: Voting Rights and Shares Capital of the Company2
22.09.Nanobiotix S.A. - 6-K, Report of foreign issuer2
15.09.Guggenheim initiates Nanobiotix stock rating at Buy on cancer drug5
14.09.Nanobiotix S.A.: NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer437All 24 patients completed treatment with no dose-limiting toxicities, no Grade 3 or higher adverse events related to JNJ-1900 (NBTXR3 or to the injection procedure, and intratumoral injection was...
► Artikel lesen
09.09.Nanobiotix S.A. - 6-K, Report of foreign issuer5
25.08.Nanobiotix S.A.: Voting Rights and Shares Capital of the Company2
25.08.Nanobiotix S.A. - 6-K, Report of foreign issuer1
31.07.Nanobiotix S.A. - 6-K, Report of foreign issuer9
30.07.Nanobiotix S.A.: Voting Rights and Shares Capital of the Company2
08.06.Nanobiotix S.A. - S-8, Securities to be offered to employees in employee benefit plans5
05.06.Nanobiotix S.A.: Voting Rights and Shares Capital of the Company6
05.06.Nanobiotix S.A. - 6-K, Report of foreign issuer1
04.06.Leerink raises Nanobiotix stock price target on cancer drug data13
02.06.Nanobiotix S.A.: Nanobiotix Provides First Quarter 2026 Operational and Financial Update1.490Completed a follow-on offering in May 2026 for aggregate gross proceeds of approximately €86.1 million, including issuance of pre-funded warrants to accelerate the development of Company's other platformsNew...
► Artikel lesen
1 2 3 Weiter >>
53 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1